Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Drug Dev ; 2(3): 205-12, 2013 Jul.
Article in English | MEDLINE | ID: mdl-27121781

ABSTRACT

This study examined the effects of panitumumab, a human monoclonal antibody against epidermal growth factor receptor (EGFR), on irinotecan pharmacokinetics. This phase I, open-label, multicenter, single-arm study enrolled patients with metastatic colorectal cancer (mCRC) without prior exposure to an EGFR inhibitor. In cycle 1, patients received irinotecan (180 mg/m(2) intravenously [IV]) on day 1 and panitumumab (6 mg/kg IV) on Day 4. In cycle 2 (2 weeks after cycle 1 panitumumab administration) and subsequent every-2-week cycles, patients received panitumumab followed immediately by irinotecan until disease progression or intolerability. Primary and secondary endpoints included Cmax and AUC of irinotecan after irinotecan infusion in cycles 1 and 2, and adverse events, respectively. Nineteen of 27 treated patients were eligible for pharmacokinetic analysis. Pharmacokinetic profiles of irinotecan with or without panitumumab coadministration were nearly identical. The 90% confidence intervals for ratios of geometric means for irinotecan Cmax and AUC with or without panitumumab were within the 80-125% interval, indicating that panitumumab had no apparent effects on irinotecan pharmacokinetics. Adverse events were as expected for irinotecan plus panitumumab combination therapy.

2.
BMC Clin Pharmacol ; 11: 17, 2011 Nov 09.
Article in English | MEDLINE | ID: mdl-22070868

ABSTRACT

BACKGROUND: Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab and to evaluate the effect of anti-panitumumab antibodies on pharmacokinetic and safety profiles in patients with mCRC receiving panitumumab in combination with oxaliplatin- or irinotecan-based chemotherapies. METHODS: Three validated assays (two screening immunoassays and a neutralizing antibody bioassay) were used to detect the presence of anti-panitumumab antibodies in serum samples collected from patients enrolled in four panitumumab combination chemotherapy clinical trials. The impact of anti-panitumumab antibodies on pharmacokinetic and safety profiles was analyzed using population pharmacokinetic analysis and descriptive statistics, respectively. RESULTS: Of 1124 patients treated with panitumumab in combination with oxaliplatin- or irinotecan-based chemotherapy with postbaseline samples available for testing, 20 (1.8%) patients developed binding antibodies and 2 (0.2%) developed neutralizing antibodies. The incidence of anti-panitumumab antibodies was similar in patients with tumors expressing wild-type or mutant KRAS and in patients receiving oxaliplatin- or irinotecan-based chemotherapies. No evidence of an altered pharmacokinetic or safety profile was found in patients who tested positive for anti-panitumumab antibodies. CONCLUSIONS: The immunogenicity of panitumumab in the combination chemotherapy setting was infrequent and similar to the immunogenicity observed in the monotherapy setting. Panitumumab immunogenicity did not appear to alter pharmacokinetic or safety profiles. This low rate of immunogenicity may be attributed to the fully human nature of panitumumab.


Subject(s)
Antibodies, Anti-Idiotypic/analysis , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Drug Hypersensitivity/immunology , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/blood , Antibodies, Monoclonal, Humanized/pharmacokinetics , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Neutralizing/analysis , Antineoplastic Agents/blood , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Colorectal Neoplasms/complications , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/immunology , Drug Hypersensitivity/blood , Drug Hypersensitivity/complications , Drug Hypersensitivity/epidemiology , Humans , Incidence , Irinotecan , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Panitumumab , Severity of Illness Index
3.
Clin Pharmacokinet ; 49(11): 729-40, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20923247

ABSTRACT

Panitumumab is a recombinant, fully human IgG2 monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It is indicated for use as monotherapy in the treatment of patients with EGFR-expressing metastatic colorectal cancer after disease progression with standard chemotherapy. The currently indicated dose is 6 mg/kg given every 2 weeks. Panitumumab is mainly distributed into the vascular space and exhibits nonlinear pharmacokinetics that are consistent with target-mediated drug disposition, involving saturable binding to EGFR and subsequent internalization and degradation inside the cells. Panitumumab is also cleared in a linear fashion by the reticuloendothelial system, similarly to other endogenous immunoglobulins. After single-dose administration of panitumumab as a 1-hour intravenous infusion, the area under the serum concentration-time curve increases in a greater-than-dose-proportional manner as the dose increases from 0.75 to 5 mg/kg; however, at doses above 2 mg/kg, the exposure to panitumumab increases in a dose-proportional manner. Panitumumab pharmacokinetics are not meaningfully affected by the tumour type, EGFR membrane expression, tumour KRAS mutation, sex, age, race or renal or hepatic dysfunction. In addition, irinotecan-containing and paclitaxel/carboplatin-containing chemotherapeutic regimens do not appear to affect panitumumab pharmacokinetics. The results of population pharmacokinetic analyses have shown that bodyweight is the most influential covariate on panitumumab exposure, supporting the current use of bodyweight-adjusted doses (mg/kg). The relationship between the weekly dose of panitumumab and skin rash, an on-target pharmacodynamic effect of EGFR inhibition, reaches a plateau at 2.5 mg/kg, indicating that this is the optimal weekly dose. Two less-frequent dosing regimens (6 mg/kg given every 2 weeks and 9 mg/kg given every 3 weeks) achieve steady-state serum trough concentrations similar to those achieved by 2.5 mg/kg given every week, ensuring maximal EGFR coverage. Anti-panitumumab antibody production is uncommon and does not appear to have an impact on the pharmacokinetics of panitumumab.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Body Weight , Clinical Trials as Topic , Dose-Response Relationship, Drug , Drug Interactions , Humans , Panitumumab
4.
Biotechnol Bioeng ; 98(2): 349-55, 2007 Oct 01.
Article in English | MEDLINE | ID: mdl-17486654

ABSTRACT

Cadmium contamination of soil is a major concern in the biosphere. Beyond the suite of available physico-chemical treatment methods, green and more efficient technologies are desired to reduce cadmium and other heavy metal contaminants to acceptable levels. Elastin-like polypeptides (ELP) composed of a polyhistidine domain (ELPH12) can be used as an environmentally benign chelating agent for ex situ soil washing. However, ELPH12 is relatively non-selective. A biopolymer with metal-binding domains that have stronger affinity, capacity, and selectivity would have distinct advantages. The aim of this work is to investigate the use of a new generation of ELP biopolymer, ELPEC20, containing synthetic phytochelatin (EC) as the metal-binding domain for ex situ soil washing. ELPEC20 was shown to bind cadmium more effectively and selectively than ELPH12. The binding constant of ELPEC20 is an order of magnitude higher and the binding capacity is fivefold higher than ELPH12. In contrast to ELPH12, no decrease in cadmium binding was observed in the presence of other competing metal ions. The improved selectivity and binding capacity provided by ELPEC20 were directly reflected in the enhanced cadmium extraction efficiency from contaminated soil. In batch washing studies up to 62% of the bound cadmium was removed by ELPEC20 while less than 12% was removed by ELPH12. Cadmium was removed not only from the exchangeable fraction but also the oxidizable fraction. The high-affinity binding sites of ELPEC20 also results in very rapid extraction with complete removal achieved within 1 h, suggesting that ELPEC20 could be used as part of a rapid (short retention time) technology with minimum possibility for the biodegradation of biopolymers.


Subject(s)
Cadmium/chemistry , Elastin/chemistry , Phytochelatins/biosynthesis , Phytochelatins/chemistry , Plant Proteins/chemistry , Biodegradation, Environmental , Cadmium/isolation & purification , Chelating Agents/chemistry , Environmental Pollution/prevention & control , Soil Pollutants/chemistry , Soil Pollutants/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...